The following discussion illustrates a project that is well suited to the capabilities of an independent consultant in the Umbrex Biotechnology Practice. This is an illustrative example. Umbrex consultants adapt their methodology, timeline, and deliverables to the specific needs of each client.
1) Client Situation
The client operated within the therapeutics-focused biotech ecosystem and required support with Protocol Design And Operational Feasibility in the context of Biotechnology. Leaders across Emerging Therapeutic Biotech (Preclinical), Clinical-Stage Biotech (Phase I–III), Commercial Biotech (Post-Approval), Platform Biotech (Therapeutic Discovery), and Biotech Investors & Incubators requested a rigorous, data-driven approach to optimize protocol endpoints, eligibility criteria, visit schedules, and assessments using feasibility insights and real-world data (RWD) to reduce screen failure, patient burden, cost, and cycle time. The diagnostic we conducted surfaced persistent pain points:
- High screen failure rates and protocol complexity
- Eligibility criteria were expansive, sometimes internally inconsistent, and not computable against real-world datasets. Lab thresholds and comorbidity exclusions dramatically narrowed eligible pools; criteria intended to protect safety were not risk-ranked and excluded large segments without evidence of operational benefit.
- Enrollment and startup unpredictability
- Country and site allocation did not reflect true prevalence, competing trials, or start-up variability. FPFV/FPI slipped repeatedly; first patient in-to-last patient in cycle time exceeded targets; screen-to-enroll conversion lagged due to pre-analytical requirements and visit density.
- Patient burden and retention risk
- Schedules of Assessments (SoA) required frequent clinic visits, duplicative labs, and long onsite assessments without home-health or telemedicine options. Travel time and out-of-pocket costs were high; retention fell below plan in longer studies.
- Protocol amendments and data quality issues
- Major amendments occurred after first dosing due to unanticipated operational constraints, introducing delays and additional IRB/EC cycles. Protocol deviations and query rates were elevated; intercurrent events were not fully anticipated within estimand frameworks (ICH E9(R1)).
- Underutilized DCT/hybrid options and eClinical tooling
- eConsent, ePRO/eCOA, telemedicine, home-health nursing, remote monitoring, and wearables were not incorporated or were added late, limiting feasibility and data completeness.
- Inadequate feasibility and site selection methods
- Feasibility relied on investigator surveys and historical relationships rather than analytics. Site performance histories (activation cycle time, enrollment/site/month, data quality) were not systematically used; diversity and inclusion plans lacked geographic alignment to target populations.
- Budget creep and vendor sprawl
- Monitor days, central lab logistics, imaging reads, and travel support were not optimized; duplicative vendors increased cost without throughput gains; SOWs lacked performance KPIs tied to enrollment and data quality.
- KPI underperformance indicators
- Screen failure rate >40%; enrollment rate <0.3 patients/site/month; startup cycle time (contracts/IRB/EC/EC submission-to-approval) exceeded benchmarks by 30–50%; protocol deviation rate and data query rate trended high; retention below 85% at LSLV; major amendment count >2 per study.
2) Project Objective
The primary objective focused on optimizing clinical protocols—endpoints, eligibility, SoA, and operational design—using feasibility analytics and real-world data to increase the addressable patient pool, lower screen failure, reduce patient burden and cost, and compress startup and enrollment timelines while preserving scientific integrity and regulatory credibility.
Secondary objectives included:
- Aligning endpoints and estimands (ICH E9(R1)) with clinically meaningful outcomes and operational feasibility; pre-specifying handling of intercurrent events.
- Translating Target Product Profile (TPP) and regulatory expectations (FDA/EMA advice, ICH E6(R3)/E8(R1)) into pragmatic protocol choices with diversity and inclusion plans.
- Building geospatial country and site allocation models that reflect prevalence, practice patterns, competing trials, and startup constraints; improving site productivity.
- Right-sizing SoA and integrating decentralized elements (eConsent, eCOA/ePRO, telemedicine, home health, remote sampling/wearables) to reduce visit burden without compromising data quality.
- Standardizing feasibility and vendor governance with performance KPIs (activation speed, enrollment velocity, data quality), SOWs, and QBRs.
- Establishing forecasting, risk modeling, and governance for amendment risk, budget control, and time-to-DBL predictability.
- Codifying processes and templates (protocol synopsis/SoA, eligibility library, burden calculator, site scorecards) to scale across the portfolio.
3) Methodology and Approach
Workstream 1: Protocol Diagnostic and Estimand Alignment
We completed a technical and operational audit of the draft protocol and aligned design choices with ICH E9(R1) estimands and TPP.
- Activities conducted:
- Reviewed protocol synopsis, objectives/endpoints, inclusion/exclusion criteria, SoA, and SAP assumptions. Mapped intercurrent events (discontinuations, rescue medications, non-adherence, death) and defined treatment-policy vs. hypothetical strategies.
- Benchmarked endpoints and measures against regulatory precedents and payer-relevant outcomes; validated PRO/HRQoL instruments and digital endpoint readiness (validation status, analytic plans).
- Tools and frameworks:
- Estimand canvas, endpoint hierarchy framework, protocol complexity score, amendment risk heatmap.
- Stakeholders:
- Clinical development, biostatistics, medical affairs, regulatory strategy, HEOR, safety/pharmacovigilance.
Workstream 2: Eligibility Optimization with Real-World Data
We quantified the impact of each criterion on the eligible pool and screen failure risk using EHR/claims registries and computable phenotypes.
- Activities conducted:
- Converted inclusion/exclusion criteria into computable logic; applied to de-identified EHR and claims cohorts to estimate incidence, prevalence, and geographic density; identified criteria with low clinical value but high exclusion impact.
- Modeled cut-off relaxations and conditional waivers (e.g., controlled comorbidities, concomitant medications) on safety and efficacy risks using literature priors and sensitivity analyses.
- Tools and frameworks:
- Eligibility inference engine, rule-based and NLP curation, simulation of funnel conversion (referred → prescreened → screened → randomized), and diversity impact modeling.
- Stakeholders:
- Clinical development, safety, statisticians, data science, key investigators, patient advocacy.
Workstream 3: Schedule of Assessments (SoA) and Patient Burden Redesign
We reduced visit and assessment burden and embedded decentralized/hybrid elements while preserving endpoint quality.
- Activities conducted:
- Rationalized assessments against endpoint/estimand needs; removed duplications; shifted appropriate activities to remote (telemedicine, home health, local labs, remote sampling kits, BYOD ePRO/eCOA); optimized PK sampling (sparse vs. rich) and imaging cadence.
- Calculated a patient burden index (time-in-clinic, travel time, costs, procedures) and modeled retention impacts; tested alternative SoAs for operational feasibility at varied site types.
- Tools and frameworks:
- SoA optimizer, burden calculator, decentralized component library, human factors checklists for wearables and home kits.
- Stakeholders:
- Clinical operations, medical monitors, central lab/imaging vendors, patient engagement and advocacy, data management, eClinical platform owners.
Workstream 4: Country and Site Allocation with Geospatial Feasibility
We built a data-informed plan for where and with whom to enroll, linking epidemiology, health system factors, and site performance history.
- Activities conducted:
- Integrated datasets: epidemiology (incidence/prevalence), claims/EHR density, historical site productivity (activation days, enrollment/site/month, retention, query rates), start-up timelines (contracts/IRB/EC), diversity by catchment area, and competitor trial heat maps.
- Developed a site scorecard and country model; prioritized sites with demonstrated throughput and data quality; calibrated central recruitment and referral networks; created country entry/exit decision rules.
- Tools and frameworks:
- Geospatial models, site productivity scorecards, competitor trial scanner, startup cycle-time benchmarks, and diversity coverage metrics.
- Stakeholders:
- Clinical operations, regional regulatory, site management organizations, CRO feasibility teams, patient recruitment vendors.
Workstream 5: Enrollment Forecasting and Risk Simulation
We established a probabilistic forecast and mitigation plan tied to protocol and operational choices.
- Activities conducted:
- Built a Monte Carlo model of enrollment considering funnel conversion, site activation variability, seasonal effects, and competing trials; stress-tested alternative eligibility/SoA designs and site mixes; quantified time-to-LSLV distributions.
- Defined mitigations (site expansion triggers, central campaigns, travel/lodging support, protocol flexibilities) with threshold-based activation.
- Tools and frameworks:
- Funnel simulation, Monte Carlo engine, risk register with trigger/action mapping, budget impact model.
- Stakeholders:
- Program leadership, clinical ops, finance/FP&A, CRO partner PMs.
Workstream 6: DCT/Hybrid Enablement and eClinical Architecture
We configured decentralized components and eClinical workflows to support the optimized protocol.
- Activities conducted:
- Selected and integrated eConsent, eCOA/ePRO (BYOD or provisioned), telemedicine, home-health nursing, wearables/sensors, and remote sample kits; aligned with privacy and site SOPs; mapped data flows to EDC and data standards (CDISC SDTM).
- Authored operational playbooks for remote visits, monitoring (RBM/RBM+), and data reconciliation; defined site training and patient support materials.
- Tools and frameworks:
- DCT component selection matrix, data architecture blueprint, data privacy impact assessment, and RBM dashboards.
- Stakeholders:
- IT/eClinical, data management, quality/GCP compliance, sites, vendors.
Workstream 7: Start-up Acceleration and Governance
We reduced contract/IRB/EC cycle times and set decision rights to protect the critical path.
- Activities conducted:
- Mapped startup process (CTA, contracts, budgets, EC/IRB submissions, EDC build, lab kit readiness); benchmarked cycle times; removed bottlenecks (templated budgets/CTAs, parallel submissions, country cluster approaches); instituted a weekly startup control tower with RAID.
- Tools and frameworks:
- Startup control tower dashboards, CTA/budget templates, EC/IRB tracker, RAID governance and decision gates.
- Stakeholders:
- Clinical operations/startup leads, legal/contracts, regional regulatory, CRO start-up managers.
Workstream 8: Budget and Vendor Optimization
We aligned costs with value while protecting quality and speed.
- Activities conducted:
- Recast budget based on optimized SoA, decentralized elements, and site mix; negotiated vendor SOWs with enrollment/data-quality KPIs; consolidated overlapping vendors; introduced QBRs with performance scorecards and change-order rules.
- Tools and frameworks:
- Activity-based costing model, vendor KPI scorecards, QBR cadence, SOW redline playbook tied to milestones and acceptance criteria.
- Stakeholders:
- Clinical finance/FP&A, procurement/vendor management, CRO/vendor PMs, quality.
Workstream 9: Diversity, Equity, and Inclusion (DEI) by Design
We designed for representative enrollment consistent with FDA/EMA expectations.
- Activities conducted:
- Mapped disease burden by race/ethnicity/sex/age across regions; prioritized sites and community partnerships; adjusted eligibility to avoid unnecessary exclusions; added patient support services (transportation, stipend, childcare, language services).
- Tools and frameworks:
- DEI coverage metrics, community engagement playbook, site selection DEI overlay.
- Stakeholders:
- Clinical leadership, patient advocacy, medical affairs, sites, recruitment vendors.
Workstream 10: Change Management, Training, and Inspection Readiness
We ensured adoption and maintained GCP compliance.
- Activities conducted:
- Trained study teams and sites on the optimized protocol, SoA, decentralized workflows, and data capture; updated SOPs/WIs; prepared inspection storyboards (protocol rationale, eligibility modeling, SoA decisions, DCT risk controls); established a cadence for protocol deviation review and CAPA.
- Tools and frameworks:
- Training kits, SOP update tracker, inspection readiness binders, protocol rationale dossiers.
- Stakeholders:
- QA/GCP, clinical operations, principal investigators, data management, vendor partners.
4) Data Request
We requested datasets and artifacts necessary to optimize protocol design and operational feasibility. Typical horizons were 12–36 months historical and current forward plans.
- Clinical program materials:
- Protocol drafts and history of amendments; synopsis, endpoints, eligibility, SoA; SAP drafts; prior feasibility reports; CSR excerpts (if amendment/extension).
- Operational data:
- CTMS extracts (site pipeline, activation timelines, enrollment/site/month, screen failure reasons, retention); feasibility survey responses; investigator databases; competitor trial landscape (Citeline/TrialTrove/ClinicalTrials.gov feeds).
- RWD/RWE:
- De-identified EHR and claims datasets for target indication(s); disease registries; lab datasets; geospatial catchment data; mortality/epidemiology sources; diversity demographics by ZIP/postcode.
- Site performance and quality:
- Historical startup cycle times (CTA, budget, IRB/EC), query rates, deviation rates, SDV/RBM metrics, monitoring findings; protocol deviation logs.
- eClinical architecture:
- EDC configuration and CRF drafts; eConsent/eCOA tools; telemedicine platforms; wearables/sensor data schemas; data privacy and security constraints.
- Financials and SOWs:
- Budget versions; vendor SOWs and SLAs; payment milestone structures; historical change orders and root causes.
- Regulatory and HEOR:
- Scientific advice feedback (FDA/EMA/PMDA); prior endpoint precedents; PRO/HRQoL validation packages; payer insights on outcomes/utility.
Common data pitfalls included non-computable criteria wording, incomplete or biased feasibility survey returns, misaligned CRFs with protocol endpoints, poor site performance attribution due to inconsistent metrics, outdated competitor-trial data, privacy constraints for geospatial modeling, and missing data standards (CDISC) linkages. We established a data dictionary, eligibility logic library, and controlled repository before modeling and design sprints.
5) Questions for Client
- What non-negotiable primary and key secondary endpoints must the protocol support, and how will intercurrent events be handled per ICH E9(R1)?
- Which eligibility criteria are safety-critical vs. conservative; where is the team open to relaxation or conditional waivers based on RWD?
- What patient-burden thresholds are acceptable (visit frequency, procedure duration); which assessments are “must keep” vs. “nice to have”?
- How important are decentralized components (eConsent, ePRO/eCOA, telemedicine, home health, wearables) to this study, and what constraints exist at sites or in regions?
- Which countries and site types (academic vs. community) are strategic for diversity, speed, or access; what historical site performance will we prioritize?
- What start-up cycle-time targets are required (contracts, budgets, IRB/EC); where can templates and parallel processing accelerate timelines?
- What budget guardrails and trade-offs are acceptable (centralized imaging, PK intensity, monitoring approach) to achieve timeline goals?
- Which vendors are locked-in vs. flexible; what KPIs and service credits should govern performance?
- What risk appetite exists for synthetic/external control augmentation, adaptive features, or enrichment strategies?
- What agency feedback or payer insights must shape endpoints, PROs, or SoA now to avoid later amendments?
- What diversity enrollment objectives are set; which patient support measures (transportation/stipends/childcare) are in scope?
- How will success be measured operationally (screen failure, enrollment velocity, retention, protocol deviations, cost per patient) and at what review cadence?
6) Interview Guide for Subject Matter Experts
Chief Medical Officer / Clinical Development Lead
- Which endpoints/estimands are mandatory for TPP and regulatory success; where is flexibility possible?
- What prior studies revealed operational pitfalls; which assessments or criteria drove early deviations or amendments?
- How should safety monitoring and stopping rules be operationalized without inflating visit burden?
Head of Biostatistics / Clinical Scientist
- What is the estimand framework; how will intercurrent events be handled; what sensitivity analyses are expected?
- Which eligibility relaxations would materially change power or effect size assumptions?
- What adaptive or enrichment options are viable and operationally feasible?
Head of Clinical Operations / Start-up
- Where do startup processes bottleneck (CTA, budget, EC/IRB, EDC build); what cycle-time benchmarks are realistic by region?
- Which sites have delivered consistently; where did central lab/logistics drive delays; how should we structure SoA to fit site capacity?
- What monitoring approach (RBM, hybrid) best fits the optimized protocol?
Patient Advocacy / Patient Engagement Lead
- What aspects of visit burden present the biggest obstacles; which decentralized options most improve participation?
- How do transportation, caregiver support, and stipends influence recruitment and retention?
- What language and consent barriers must be addressed across geographies?
Data Management / eClinical Lead
- How will eConsent, ePRO/eCOA, telemedicine, and wearable data flow into EDC; what standards (CDISC) and integrations are required?
- Where have CRFs or edit checks conflicted with protocol language; what data quality risks exist for remote assessments?
Central Lab / Imaging / PK Vendors
- What logistics and assay/reading constraints drive turnaround times; where can we reduce repeats or harmonize timepoints?
- What are the most frequent sources of sample/image rejection; how can SoA changes mitigate them?
Site Investigators / Study Coordinators
- Which eligibility criteria or assessments are most problematic in practice; where is there ambiguity?
- How do staffing, clinic hours, and equipment availability constrain visit scheduling and throughput?
- What training or materials would simplify trial execution and patient experience?
7) Timeline
We executed a 12–14 week plan tailored to Protocol Design And Operational Feasibility within Clinical Development & Operations.
- Weeks 1–2: Diagnostic and Data Enablement
- Reviewed protocol and SAP drafts; collected CTMS, site performance, feasibility surveys, and RWD sources; built eligibility logic library; baselined KPIs; aligned governance and decision gates.
- Decision Gate A: Approved diagnostic findings, estimand framework alignment plan, and data sources for modeling.
- Weeks 3–4: Eligibility and SoA Design Sprints
- Ran design sprints to test eligibility relaxations and SoA alternatives; quantified impact on eligible pool, burden, and cost; drafted revised criteria and SoA options with risk rationales.
- Decision Gate B: Ratified eligibility and SoA proposals; set DCT/hybrid scope and data architecture requirements.
- Weeks 5–6: Country/Site Allocation and Enrollment Modeling
- Built geospatial country and site models; generated site scorecards; produced Monte Carlo enrollment forecasts under alternative designs; recommended site/country mix and triggers.
- Decision Gate C: Approved country/site plan and enrollment forecast; set central recruitment/referral strategy.
- Weeks 7–8: Start-up Acceleration and Vendor Realignment
- Implemented startup control tower, templates, and parallel processing; renegotiated SOWs with KPIs and service credits; consolidated vendors; defined training plans for DCT/hybrid workflows.
- Decision Gate D: Confirmed startup targets and vendor KPIs; launched site/readiness campus and training schedule.
- Weeks 9–10: Budget, Risk, and Governance Finalization
- Updated activity-based budget; finalized risk register with triggers/actions; aligned SOP updates and inspection readiness materials; integrated diversity plans and patient support programs.
- Decision Gate E: Approved budget and risk mitigations; locked protocol and SoA for finalization and EC/IRB package preparation.
- Weeks 11–12: Handoff and Activation Readiness
- Delivered optimized protocol package (synopsis, eligibility, SoA, DCT playbook); kicked off site training; launched dashboards for startup and enrollment monitoring; set cadence for governance reviews and amendment watch.
- Decision Gate F: Authorized site activation; confirmed enrollment “go-live” criteria and reporting cadence.
- Weeks 13–14 (optional): Dry-Runs and Inspection Prep
- Executed mock remote visit flows and data integrations; ran startup “day-in-the-life” drills; completed inspection storyboards; tuned KPIs and alerts based on dry-run outputs.
Critical path items included eligibility computability and RWD access, SoA redesign feasibility at target sites, DCT component integration, country/site selection consensus, startup contract/IRB/EC cycle-time reforms, and vendor alignment to enrollment/data-quality KPIs.
8) Deliverables
- Protocol Optimization Dossier
- Estimand-aligned endpoint hierarchy; revised eligibility criteria with RWD impact analysis; SoA alternatives with burden/cost modeling; DCT/hybrid design recommendations and risk controls.
- Eligibility Logic Library and Computability Rules
- Structured, computable eligibility definitions with justification; mapping to EHR/claims codes; sensitivity analyses; diversity impact summary.
- Patient Burden and Retention Plan
- Burden index by visit; travel/time/cost model; retention risk and mitigation plan; patient support services (transport, stipends, childcare, language support).
- Country and Site Allocation Model
- Geospatial feasibility results; site scorecards; country entry/exit criteria; central recruitment/referral strategy; diversity coverage metrics.
- Enrollment Forecast and Risk Register
- Monte Carlo forecast; funnel conversion assumptions; triggers for site expansion and central campaigns; RAID with mitigation budgets and owners.
- DCT/Hybrid Operational Playbook
- eConsent/eCOA workflows; telemedicine and home-health SOPs; remote sampling/wearables integration; data architecture blueprint and privacy impact assessment.
- Startup Control Tower and Templates
- CTA/budget templates; EC/IRB tracker; startup dashboards; decision gates and escalation playbook; training materials for sites.
- Vendor Governance and KPI Scorecards
- SOW redlines with performance metrics; QBR scorecards; service credit/penalty matrices; capacity calendars; change-order governance.
- Budget and Activity-Based Costing Model
- Cost impacts of eligibility/SoA/DCT options; site-mix economics; monitor days, lab/imaging logistics, and vendor costs; variance tracking framework.
- Diversity and Inclusion Implementation Plan
- Site selection overlay, community partnerships, patient support, and tracking metrics aligned to FDA/EMA expectations.
- Inspection Readiness Pack
- Protocol rationale storyboards (eligibility, SoA, DCT), SOP/WI updates, training logs, and deviation/CAPA monitoring plan.
9) Industry Insights
- Estimands anchor scientific and operational clarity
- ICH E9(R1) demands explicit handling of intercurrent events; aligning estimands early reduces amendments and clarifies data collection needs, SoA intensity, and analysis strategies.
- RWD transforms eligibility from opinion to evidence
- Computable criteria tested on EHR/claims expose exclusionary rules that do not add safety; targeted relaxations can significantly expand the eligible pool without undermining rigor.
- DCT is mainstream—but success is operational
- Hybrid designs with eConsent, eCOA, telemedicine, home health, and wearables improve recruitment and retention when SOPs, data flows, and site training are robust; “bolt-on” DCT late in startup underdelivers.
- Geospatial allocation beats legacy site lists
- Prevalence, practice patterns, and site performance history—plus competitor trial heat maps—should inform country/site selection; diversity goals are achieved by design, not by hope.
- Schedules of Assessments determine patient experience
- Reducing onsite time and duplicative procedures, optimizing PK/imaging cadence, and enabling home-based options lower burden and improve retention and data completeness.
- Startup speed is a system, not a heroics contest
- Templates, parallelization, clear decision rights, and a startup control tower consistently reduce IRB/EC and contract cycle times; CRO/vendor KPIs must tie to activation and early enrollment.
- Diversity expectations are explicit and rising
- FDA/EMA encourage representative enrollment plans; mapping disease burden and removing unnecessary exclusions while providing practical support improves equity and credibility.
- What “good” looks like
- A protocol with estimand-aligned endpoints, computable and patient-friendly eligibility, a streamlined SoA with decentralized elements, geospatially optimized site selection, a credible enrollment forecast with risk triggers, an accelerated startup system, and vendor governance tied to throughput and quality—documented in inspection-ready storyboards.
- Near-term watch points
- ICH E6(R3) modernization impacts on study quality and oversight; evolving digital endpoint validation standards; privacy regulations affecting geospatial and remote data; competitive trial congestion; payer demand for utilities/PROs in pivotal designs. Quarterly protocol feasibility refreshes maintain momentum and credibility.
Implications for clients we served included enabling Emerging Therapeutic Biotech to design first-in-human and PoC protocols that recruit feasibly; supporting Clinical-Stage Biotech to lock pivotal designs that meet regulatory expectations while compressing cycle time; equipping Commercial Biotech to execute post-approval studies with lower burden and higher retention; guiding Platform Biotech to standardize protocol optimization playbooks across partnered programs; and providing Biotech Investors & Incubators with diligence views on protocol risk, enrollment feasibility, and time-to-milestone reliability across portfolios.
